Single Center Experience in Transitioning Pulmonary Arterial Hypertension Patients from...

Single Center Experience in Transitioning Pulmonary Arterial Hypertension Patients from Intravenous Epoprostenol to Oral Selexipag
My name is Zeenat Safdar. I'm the director of the Pulmonary Hypertension Program at Houston Methodist Hospital, Weill Cornell Medicine, in Houston, Texas. I'm going to talk about my poster that I presented at ATS 2017.
The title of the poster is “Single Center Experience in Transitioning PAH Patients from IV Epoprostenol to Oral Selexipag”. The objective of the study was to determine the safety and efficacy of switching patients from intravenous prostacyclin to oral IP receptor agonist, as it has become available, in stable PAH patients.
In conclusion, carefully selected, stable PAH patients who have been on stable intravenous prostacyclin therapy, meaning no change in there prostacyclin dose, no recent hospitalization, no change in their functional capacity, who have normal right atrium and right ventricle observed on an echocardiogram, can be safely transitioned to an oral IP receptor agonist. However, we need long-term follow up to determine the durability of this transition.
Thank you for your attention. I will appreciate any feedback.